GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Monogram Orthopaedics Inc (NAS:MGRM) » Definitions » ROE %

Monogram Orthopaedics (Monogram Orthopaedics) ROE % : -115.68% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Monogram Orthopaedics ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Monogram Orthopaedics's annualized net income for the quarter that ended in Dec. 2023 was $-14.62 Mil. Monogram Orthopaedics's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $12.63 Mil. Therefore, Monogram Orthopaedics's annualized ROE % for the quarter that ended in Dec. 2023 was -115.68%.

The historical rank and industry rank for Monogram Orthopaedics's ROE % or its related term are showing as below:

MGRM' s ROE % Range Over the Past 10 Years
Min: -384.73   Med: -318.05   Max: -156.67
Current: -162.01

During the past 7 years, Monogram Orthopaedics's highest ROE % was -156.67%. The lowest was -384.73%. And the median was -318.05%.

MGRM's ROE % is ranked worse than
92.17% of 805 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs MGRM: -162.01

Monogram Orthopaedics ROE % Historical Data

The historical data trend for Monogram Orthopaedics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monogram Orthopaedics ROE % Chart

Monogram Orthopaedics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial - -384.73 -278.26 -357.84 -156.67

Monogram Orthopaedics Quarterly Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -299.93 -623.05 -322.18 -33.10 -115.68

Competitive Comparison of Monogram Orthopaedics's ROE %

For the Medical Devices subindustry, Monogram Orthopaedics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Monogram Orthopaedics's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Monogram Orthopaedics's ROE % distribution charts can be found below:

* The bar in red indicates where Monogram Orthopaedics's ROE % falls into.



Monogram Orthopaedics ROE % Calculation

Monogram Orthopaedics's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-13.745/( (4.149+13.397)/ 2 )
=-13.745/8.773
=-156.67 %

Monogram Orthopaedics's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-14.616/( (11.872+13.397)/ 2 )
=-14.616/12.6345
=-115.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Monogram Orthopaedics  (NAS:MGRM) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-14.616/12.6345
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-14.616 / 1.46)*(1.46 / 17.407)*(17.407 / 12.6345)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1001.1 %*0.0839*1.3777
=ROA %*Equity Multiplier
=-83.99 %*1.3777
=-115.68 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-14.616/12.6345
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-14.616 / -14.616) * (-14.616 / -15.508) * (-15.508 / 1.46) * (1.46 / 17.407) * (17.407 / 12.6345)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9425 * -1062.19 % * 0.0839 * 1.3777
=-115.68 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Monogram Orthopaedics ROE % Related Terms

Thank you for viewing the detailed overview of Monogram Orthopaedics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Monogram Orthopaedics (Monogram Orthopaedics) Business Description

Traded in Other Exchanges
Address
3913 Todd Lane, Suite 307, Austin, TX, USA, 78744
Monogram Orthopaedics Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
Executives
Paul H Riss director
Noel Knape officer: Chief Financial Officer 3913 TODD LANE, AUSTIN TX 78744
Benjamin Sexson director, 10 percent owner, officer: Chief Executive Officer 3913 TODD LANE, AUSTIN TX 78744
Noel Goddard director 3913 TODD LANE, AUSTIN TX 78744
Kamran Shamaei officer: Chief Technology Officer 3913 TODD LANE, AUSTIN TX 78744
Douglas Unis director 3913 TODD LANE, AUSTIN TX 78744